Cell Therapy Processing Market Report 2025

The cell therapy processing market size has grown rapidly in recent years. It will grow from $4.54 billion in 2024 to $5.18 billion in 2025 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to the increasing adoption of cell-based therapies, greater investment in biomanufacturing infrastructure, rising demand for personalized medicine, growing clinical success of cell therapies, and the heightened need for good manufacturing practice (GMP)-compliant processing systems.

The cell therapy processing market size is expected to see rapid growth in the next few years. It will grow to $8.73 billion in 2029 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to the increasing focus on automated cell processing technologies, the rising integration of artificial intelligence (AI) into cell manufacturing workflows, growing demand for scalable allogeneic cell therapies, stronger regulatory support for advanced therapy manufacturing, and the expansion of partnerships between biotech firms and contract development and manufacturing organizations (CDMOs). Key trends anticipated during this period include advancements in closed-system bioreactor technologies, the development of real-time monitoring tools for cell cultures, innovations in cryopreservation and cell storage methods, progress in cell separation and purification techniques, and the emergence of modular and scalable good manufacturing practice (GMP) manufacturing platforms.

The rising number of cell therapy research activities is expected to drive the growth of the cell therapy processing market in the coming years. Cell therapy refers to the development and manufacturing of therapeutic products derived from living cells to treat or manage diseases such as cancers, autoimmune disorders, and genetic conditions. Growing demand for scalable and consistent manufacturing platforms that can support high cell densities without compromising quality is fueling research activity. Cell therapy processing plays a critical role by enabling standardized preparation, strict quality control, and scalable production of high-quality cells, ensuring reliable and reproducible outcomes for both research and clinical applications. For example, in December 2024, the International Federation of Pharmaceutical Manufacturers and Associations, a Switzerland-based non-profit organization, reported that six first-in-class cell and gene therapies were introduced in 2023, marking a 50% increase compared to the three introduced in 2022. Therefore, the surge in cell therapy research activities is propelling the growth of the cell therapy processing market.

Companies in the cell therapy processing market are introducing technological innovations such as integrated bioreactor-centrifuge systems to enhance workflow efficiency, scalability, and sterility in manufacturing. An integrated bioreactor-centrifuge system combines cell incubation and centrifugal separation in a single closed unit, enabling continuous, automated processing without the need for intermediate transfers. For instance, in March 2025, Limula SA, a Switzerland-based cell and gene therapy (CGT) manufacturer, launched LimONE, an automated closed-system platform for cell therapy manufacturing. LimONE integrates hardware, single-use consumables, and software protocols to consolidate critical steps such as incubation, centrifugation, and reagent handling within a compact unit. This innovation allows for consistent and scalable production of advanced therapies, including CAR-T and gene-edited stem cells, from early research through to GMP-compliant manufacturing, eliminating the need for complex technology transfers.

In May 2025, AstraZeneca PLC, a UK-based pharmaceutical company, acquired ESO Biotech for $1 billion. This acquisition was aimed at expanding AstraZeneca’s rare disease portfolio by integrating ESO Biotech’s advanced gene-editing technologies to strengthen its genomic medicine capabilities. ESO Biotech is a Belgium-based biotechnology company that develops next-generation gene-editing therapies for rare diseases.

Major players in the cell therapy processing market are Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Novartis AG, Gilead Sciences Inc., Danaher Corporation, Lonza Group AG, Anterogen Co. Ltd., Terumo Corporation, Sartorius AG, Bio-Techne Corporation, STEMCELL Technologies Inc., Miltenyi Biotec GmbH, AGC Biologics S.p.A., MaxCyte Inc., Nkarta Inc., Cellares Corporation, Cellectis S.A., JW (Cayman) Therapeutics Company Limited, Cell Therapies Pty Ltd., and InGeneron Inc.

North America was the largest region in the cell therapy processing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cell therapy processing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cell therapy processing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Cell therapy processing refers to the sequence of procedures involved in collecting, modifying, and preparing living cells for therapeutic applications. This process includes cell isolation, activation, genetic modification, expansion, and formulation, all carried out under strict sterile and quality-controlled conditions. To ensure safety, purity, and effectiveness, these steps are performed in accordance with good manufacturing practices (GMP).

The primary offerings in cell therapy processing include products, services, and software. Products consist of physical tools, reagents, cell lines, and advanced instruments used to handle, cultivate, and prepare cells. Applications span across areas such as cardiovascular therapies, bone repair, neurological disorders, skeletal muscle repair, cancer treatment, and more. End users include research institutes, biopharmaceutical companies, contract research organizations (CROs), and others.

The cell therapy processing market research report is one of a series of new reports that provides cell therapy processing market statistics, including cell therapy processing industry global market size, regional shares, competitors with a cell therapy processing market share, detailed cell therapy processing market segments, market trends and opportunities, and any further data you may need to thrive in the cell therapy processing industry. This cell therapy processing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell therapy processing market consists of revenues earned by entities by providing services such as cell isolation, enrichment services, cell expansion, cryopreservation, and cell characterization. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell therapy processing market also includes sales of cell culture bioreactors, cell counting analyzer, flow cytometers, and viral vector production systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.